{"ticker": {"uuid": "42dd0a3f-10f0-4b0f-a50c-d20501eef198", "symbol": "SNTI", "name": "Senti Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "$Senti Biosciences (SNTI.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPdEltYU5LdHNNck5vX1BJT0ZlbDlrNmppZ2R2TXZWUTd5SHRUR3BPOTNNYXRtTDZXaTl1bVN4djNqUXV0UDREejNTZW1uZkE0VGRsQWNtZjd2bDdacW9aNnFPZGwyYWJRT3FqakJDWmFtNnJLVFZ1cjJ4OTlqT3dVSE5WcFh3dw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-21T23:58:00+00:00", "published_display": "21 Jul 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) outlines CVR-only merger, reverse split and note share issuance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPMFFZdEY5SHVkdHMzU3BDWldpWXVZTmxaM0lvekh4RnktZnVRMmlkNUowbVhtVlA1cVMwb2VJS0dQLXlla1dBVGluWVhfa1o0VDB1alozMGZlLU5UZzl6VS1ocTZRTjFBMWg0NUU5bFBlZFBZMWpmRWRNN29uRzJpcHVmSVZWcVRhbDdyaE50OTlvNnhPTm8yTXY2bFcxaHlnYVNCTER4b1lVcnA2SFpUOUNfVjF5Snk1SEw3NGJfV0tlZHRUOUdhZlEyNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:01:14+00:00", "published_display": "21 Jul 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026)", "summary": "This article reports on an ARS SEC filing by Senti Biosciences Holdings, Inc. (SNTI) on July 21, 2026. The filing has a low impact and neutral sentiment, and was accepted by the SEC EDGAR at 05:18 PM on the same date. The article also provides recent news and other SEC filings re", "url": "https://www.stocktitan.net/sec-filings/SNTI/ars-senti-biosciences-holdings-inc-sec-filing-31b77d1430f0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T22:10:25", "published_display": "21 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (NASDAQ: SNTI) Share Price, SNTI Stock News, SNTI Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE51MEdiLVZXaXZSdWJyWWZSUWQ4ZGJSa0U3LUx6RncyRGRwVHgzRk52N3VoTTEzNjdkQlNmYWJ5dHVvYUFnd1NHWngtOEZuTFZUQmZkWkd3?oc=5", "source_name": "Kalkine", "published_at": "2026-07-20T14:53:00+00:00", "published_display": "20 Jul 2026 14:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com", "summary": "This article from Investing.com reports on a Form 13D/A filing related to Senti Biosciences Holdings, specifically for activity on July 16. It notes a -4.94% change for SNTI. The content primarily focuses on financial market data and investment-related topics, including stock per", "url": "https://ng.investing.com/news/stock-market-news/form-13da-senti-biosciences-holdings-for-16-july-93CH-2603666", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T12:10:58", "published_display": "17 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Senti Biosciences Holdings Inc For: 16 July", "summary": "This article announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. on July 16, 2026. This SEC filing is typically related to registering securities for offering, indicating potential capital-raising activities for the company. The brief notice highlights the immed", "url": "https://ng.investing.com/news/stock-market-news/form-s3a-senti-biosciences-holdings-inc-for-16-july-93CH-2602398", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T00:09:35", "published_display": "17 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. The filing date is noted as July 16, and the article provides no further details beyond this announcement. The piece includes financial data, market indices, and other investment", "url": "https://za.investing.com/news/stock-market-news/form-s3a-senti-biosciences-holdings-inc-for-16-july-93CH-4371736", "source_name": "Investing.com South Africa", "published_at": "2026-07-16T18:14:03", "published_display": "16 Jul 2026 18:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) backer plans merger and $6M funding", "summary": "Celadon-affiliated entities, holding a 54.6% stake in Senti Biosciences (SNTI), have reported a merger agreement with Senti Biosciences Holdings. This merger involves the acquisition of Senti's Gene-Circuit-enabled pipeline, including SENTI-202 rights, through Parent (Celadon Par", "url": "https://www.stocktitan.net/sec-filings/SNTI/schedule-13d-a-senti-biosciences-holdings-inc-amended-major-sharehold-89c3ed4448da.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:51", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Stockholders Could Receive Up to $60M From SENTI-202", "summary": "Senti Biosciences Holdings (NASDAQ: SNTI) announced a strategic transaction where its Gene-Circuit-enabled pipeline, including SENTI-202, will be acquired by a new private biotechnology company controlled by its largest investor, Celadon. In return, SBH equity holders will receiv", "url": "https://www.stocktitan.net/news/SNTI/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-m90r9xa30iro.html", "source_name": "Stock Titan", "published_at": "2026-07-16T01:10:25", "published_display": "16 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences to spin off gene therapy unit for CVR", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQdzgtVFFUNTMxYmc1VEVBRlMyaThLZjd6ZmNUZ2Nfem1fNGIyYi1qVXZqVm5QRi1OVm03M29RZmpTV1h4ZW9IejBCdm83ZFR5aW5WWlVwamVZNXpYUnNxQldfWmotQ0x2YnVuemI5LUFxTGVVMWM1QnlHVnQwLTQyYXk3U0pRc2g4bWJpcmRLdjREZFQwZV9XY2VIdzVFXzlKS0F2dmoxTXA2d00zVFlLazh3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T12:03:15+00:00", "published_display": "15 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial\u2122 Te", "summary": "Senti Biosciences Holdings, Inc. (SBH) announced a strategic transaction where a newly formed private company, NewCo, will acquire SBH's Gene-Circuit-enabled pipeline, including SENTI-202. In return, SBH equity holders will receive a contingent value right (CVR) providing up to $", "url": "https://finance.yahoo.com/healthcare/articles/senti-biosciences-holdings-inc-announces-113000590.html", "source_name": "Market source", "published_at": "2026-07-15T11:48:02", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs", "summary": "Senti Biosciences has announced a merger agreement with a Celadon Partners affiliate to divest substantially all of its existing business and pipeline. Senti will remain public, retaining certain IP and early-stage programs, while stockholders could receive up to $60 million in c", "url": "https://www.tradingview.com/news/tradingview:b4ae19032a637:0-senti-biosciences-to-divest-operating-business-to-celadon-affiliate-holders-get-up-to-60m-cvrs/", "source_name": "TradingView", "published_at": "2026-07-15T11:48:02", "published_display": "15 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform", "summary": "Senti Biosciences Holdings (SBH) announced a strategic spin-off of its Gene-Circuit pipeline, including SENTI-202, into a new private company, NewCo. SBH will now focus on its Regulator Dial platform for controllable genetic therapies, while stockholders could receive up to $60 m", "url": "https://www.quiverquant.com/news/Senti+Biosciences+Holdings+Announces+Strategic+Spin-Off+of+Gene-Circuit+Pipeline+and+Plans+Focus+on+Regulator+Dial+Platform", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:42:17", "published_display": "15 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article provides the \"Price to book forward\" value for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific financial metric for the company at a certain period is av", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T10:40:56", "published_display": "01 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article provides a financial metric\u2014enterprise value to EBIT forward\u2014for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a data point from TradingView's financial section, offering a snapshot of this specific valuation metric without further analytical comm", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:11:02", "published_display": "27 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI)", "summary": "This article provides an overview of Senti Biosciences Holdings, Inc. (NASDAQ: SNTI), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It highlights the company's earnings, revenue, market capitalization, and volatility, whi", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T05:40:34", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article displays the \"Price to sales forward\" metric for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It is a brief financial data point from TradingView, indicating that the market for SNTI was closed with no trades when this information was presented. The article is a ", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:15", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Senti Biosciences Inc (SNTI), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. SNTI's current price momentum score is 6.28, and it is trading between a resistance lev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/technical", "source_name": "TradingKey", "published_at": "2026-06-26T03:40:34", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Senti Biosciences Holdings, Inc. (SNTI) stock, including price targets from three analysts, with a maximum estimate of $15.00 and a minimum of $12.00. It also covers SNTI's current price, historical performance, volatility, market capitalizati", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:15", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes", "summary": "Senti Biosciences (SNTI) has registered 15.97 million shares of common stock for resale, tied to Senior Secured Convertible Notes issued in May 2026. This move, while not generating direct proceeds for the company, represents a significant potential dilution, as the shares could ", "url": "https://www.stocktitan.net/sec-filings/SNTI/s-3-senti-biosciences-holdings-inc-shelf-registration-statement-36aa7bdfbe09.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:11:17", "published_display": "18 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Senti Biosciences Inc (SNTI) has an earnings forecast score of 8.50, placing it 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00 for SNTI, with a \"Buy\" rating based on the opinions of 4 analysts. The company's EPS for the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:11:17", "published_display": "18 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Senti Biosciences Inc (SNTI), noting its current valuation score of 6.82, ranking 295 out of 388 in its industry. It highlights the company's current P/E ratio of -0.65, which is significantly below its recent high and above its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:38", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Senti Biosciences Inc (SNTI), noting that relevant financial data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price and marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:08:58", "published_display": "17 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Senti Biosciences Inc (SNTI). It notes that no dividends have been distributed in the past five years and details several upcoming merger-related stock splits scheduled for July 16, 2024, at a 10-to-1 ratio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:08:57", "published_display": "17 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI - Senti Biosciences Holdings Inc Options", "summary": "This article provides a comprehensive financial overview of Senti Biosciences Holdings Inc (SNTI), detailing its current stock performance, key financial metrics, and company statistics. It includes data on market capitalization, income, sales, analyst recommendations, and variou", "url": "https://finviz.com/stock?t=SNTI&ty=oc", "source_name": "Finviz", "published_at": "2026-06-09T20:51:00", "published_display": "09 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI - Senti Biosciences Holdings Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news feed for Senti Biosciences Holdings Inc (SNTI). It includes key financial metrics, stock performance data, analyst ratings, and a chronological list of recent company news releases, focusing on clinical trial advancements ", "url": "https://finviz.com/stock?t=SNTI", "source_name": "Finviz", "published_at": "2026-06-07T08:12:01", "published_display": "07 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase", "summary": "Senti Biosciences Holdings announced its Q1 2026 financial results, highlighting significant progress in its SENTI-202 program for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), which is now advancing into a pivotal phase after positive FDA feedback supporting a single-arm", "url": "https://finance.yahoo.com/sectors/healthcare/articles/senti-biosciences-holdings-reports-first-124500488.html", "source_name": "Market source", "published_at": "2026-05-29T17:12:04", "published_display": "29 May 2026 17:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR", "summary": "Senti Biosciences, through its subsidiary Senti Holdings, has sold $10.0 million in senior secured convertible notes to Celadon Partners SPV 24, as per a previously announced agreement. The company also detailed potential future \"Subject Transactions,\" which could include additio", "url": "https://www.stocktitan.net/sec-filings/SNTI/8-k-senti-biosciences-holdings-inc-reports-material-event-eea24fde770f.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:10:09", "published_display": "26 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy", "summary": "Senti Bio is advancing its allogeneic CAR-NK program, SENTI-202, to a pivotal trial based on a \"Donor X attribute\" strategy that significantly improved response rates in heavily pretreated AML patients. This attribute, found in about 50% of adult donors and independently detectab", "url": "https://www.clinicaltrialvanguard.com/news/senti-bio-advances-senti-202-to-pivotal-trial-with-donor-x-selection-strategy/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-05-18T22:48:02", "published_display": "18 May 2026 22:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure", "summary": "Senti Biosciences, Inc. (SNTI) is facing significant refinancing and liquidity risks due to a costly note structure requiring a 200% cash payment at maturity or default. The company's inability to generate sufficient cash flow could lead to asset sales, dilutive equity raises, or", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1981674/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T06:10:27", "published_display": "17 May 2026 06:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML", "summary": "Senti Biosciences gained FDA support for its SENTI-202 donor selection strategy in relapsed/refractory AML, based on post-hoc analysis showing a significant difference in remission rates depending on the NK cell donor. The company will now exclusively use \"Donor X\" derived cells ", "url": "https://www.clinicaltrialvanguard.com/news/senti-biosciences-secures-fda-support-for-senti-202-donor-selection-strategy-in-aml/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-05-15T22:12:03", "published_display": "15 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding", "summary": "Senti Biosciences (NASDAQ: SNTI) has reported a narrowed net loss and significant progress for its lead program, SENTI-202, including positive FDA Regenerative Medicine Advanced Therapy (RMAT) backing for a pivotal trial in relapsed/refractory AML. The company also secured a stra", "url": "https://www.stocktitan.net/sec-filings/SNTI/8-k-senti-biosciences-inc-reports-material-event-b6edcb946aa3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:10:28", "published_display": "15 May 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/senti-biosciences-holdings-announces-positive-124000159.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:40:00+00:00", "published_display": "14 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOMHJXMTgtWk45MDN6aE5xU0pkN25LeGdDemFYbVEyRlVKcEh6Z0JLUHk2M2VQNk1mUnpqbk5oaUhaRTc3cU9lRnVUR3UwM25ZMTh4U0dsUDdwd0dCVV9MSmZ0WDFPbDhyay1IMGcyc1hhMG5scXQtU0lOQkxtREhNbDdkUTlYNHdISGdKRWZ0Y2ttZnlCblRldU92ZEQ4MUgyVXNLV3NHLURJWnZYZWpBUEItelJ4RlVFMWo1X0FndkkwV1NVWHdnZElzRk4wT0FWNG9ZNFBVeDVqUzlCeGp5VXZudmltdFZudkV0WExodGh1ZmxldVFLTzZ2RWU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Senti Biosciences, Inc. SEC Filing (Apr 30, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNQl9YX0lGRk5ZWFhUVVlNNUVTOTlFMFRHNmhvbEJBOFpGTEhfQVROZXplYUhib3FDSkZfUFo0aTRQeGkxTXhtSXBwQ1BtZ25qQWFfRm1Qa2RmMVNjRTdwVWZOMWt5elhpTms5TmxBcnJRTGpBeDJIQ0N1ZFpJVFFjcEdMczdFMjhUSkhfR2dUM29QTzF2MFdiMFZkVHhjSktEV2t3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Senti Biosciences completes holding company reorganization, stock continues on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOOEVmNzg2X2VLOXJZQTRwaUlSSUlpNXhLOHZhMjNaRndqTVZhZm9NLWxYa1d4V0FCbVBMV2NhcXFZcXJSSUZDT043a1ROaW1vSUU4Z1gweFUyLXdWZm93NE5mMUNsaVV4cFBmSHNsNEVoRzI4SlM4c25XNW1rcXZxZ2NvVXVPd09tNG5PT3hvTDdiUzI4NUJoMF9yb0lnN2ZXOHRXdVZ6N1g1M2JhaG5fcHhvZktCWVlOS0VTUDE0a1hLLWdXeHFzSzZTOG5fdkNtSFI0bUtwWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxQRkExeHlGbU96cUJRYzNaNHZfa1lBWVRKcDg5dlRkWDBCVTZNaDBRSWIwcGtiTkhhNjZ6X0ZWVmFJc3F4YU85RFlhcHJaMlVUekxEdk9QNVZZTWcwOFd3V0lYZ0Vad2FBVDcwYkRrd2owMjZVZ0g4S2hxdmJxYXVBY1FMem12NTg0WTFnN29XbENKTXdNc0hJZ09WWloyLWNJVGpDMjg0MkZWeHRpclhPYzBNUV84Sk5VbUpxVnMyOElmWXY2NXdlN1haQnpfWUlfb20xYmd5V1RPVy1ReTloWVMxbnZSdE9aWjVjaWR5RVl4cDZuektMLWFvSnBtTWo5eHc?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Senti Biosciences stock rating held at Buy by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOWxXc1d3cUZ1YmFPblZsWFFlOGJ6MXJNdllYTmQySzRfd0JNLTRFU2hvQWtxX2o1VDdzOUdsOVZVc0ZzcE5ZMDAxMDhUWmhfWU5DbElueU5FOTRRUTIwUWhjU1psam5TMF85MkFUVTd6UjRkVy1GandWWWp6eVRmbllIQlg0Q2kxSWpBY01ZWS1HNktoSXk4Q2tvMGhTWEg3YkNCZ19TcHp0UG5mUFFmMmJBaGR3OHFNVkhj?oc=5", "source_name": "Investing.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants special status to Senti Bio's leukemia therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWWpScS1GSENMRXZwaVp5SlZEN3RnWEkta1d1NDhMbVhuWnF3OWhBVkxMQkhlMUd4aHJPdnBuWHEtbTNrQ2lHai1aNzg3bi1FZmU1LWx4TzFxeHVNQ2hnSF9TTE5SX3ZKQlNwcHRvbEF5dVV3el9tVTB5eEs2V2R1eVdiM29pMkVrY0RKem1penRtNHBnbzl3ODROMExXeV9LalAwc0FZZEE0by1HYk5XS1BHS01ZM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQnhtTXBDbExDcjJ0MHRzY3FPclRLRnIzX3Q5WWRpcEtIdDh4T3p1MWYwSVZEbkxqZkh1NzFMU0hINk9TcU5fazE1TXFNNEhCRWgyU1JJVndwdXlsU2Z4enNMQjZjOXo0RXlOZDM3eXZoTzFxMFhKdGhlT25JYkJKNnNGVXEyZzRKdmM3UWxqRDB6MEJMaW9vZUhNd2xvT0NzX0Fn?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences: Understanding the Market Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9CRmVveW5fX09OeV9nZHlkN2ZfVkFEZXVTOFJkRGZ6eTVmQXZJZW5OeXlrSVR4ZC1rYkRIT21rY3NqUVkwb2VFeURncktsUFp4d25xMW81V2VOVndfdEZsSUczU0hNczg0ZnhSUHhLTUs5dXd5dXFZVEpOQXB2bkU?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5kN3ZBN3pvX1pBSUc2eWdveFF4NG1jZGNxcTdrNWZyd3FqVm1QS2RlcW5iRkZ1OF9BTGtKTzFBX0I2TngybzJwbHU4a3ZKUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-09T15:18:43+00:00", "published_display": "09 Dec 2025 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQTi04N0R6dU9IODJMaDlrbFRESjhpcWhzYUtBaFMyY3BXb2Zvam53cENrMkRTXzR6dWtSRUQ4TVJsTkt1WHlxZ0Rzd01RbHBCMGdiVDduVWtmMk91MjZvaVdVMjRpZ19lRGh6RFJ5VTc3RVBWbnNLcEFNa3ozMy1BenVhMXc5OVRJY25wMUlWaUpPVmVFdHpUQkE3WFpWSnc?oc=5", "source_name": "OncLive", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings (SNTI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBrRW41VEN4d2FucFBYOExFelJ1UV9fVkRtSThCV2l2ZExubXpySUx5dTJrdDFwb0RzZkJzRG1hRDM5TjNSMU5oU3dCUUdZVmpIa0lZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:57:19+00:00", "published_display": "24 Apr 2025 16:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Stock Forecast and Price Target 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5EXzNkM2t3bTZjOFBoZzVBZ3llbGJBdkRJWUpEN1VzeDB1aWhSTDBMalpiNTVhNXE1ODl2bmwwR2VaVHh2Qlpoa09uZFhKRWYzbW4xbFR0bmhWTUtUQlNNM25XQmJXUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:28+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1lOV9sSlZKNTF6VlZIcmk3M1gwTmM1LWhDTXlSRFlZTkJrTWpsY09KeVNwM25YNDlnNjh1Q3VDdzdZbWV6UzJ1b3pSaWxGN3g5ZjhBeFVJYw?oc=5", "source_name": "Moomoo", "published_at": "2023-07-31T05:06:35+00:00", "published_display": "31 Jul 2023 05:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Earnings Date and Reports 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE8tdlNwQ3VYaEJVODlMVkI2bnpKMUgwVWs0Mm1IU0FFVVJja1hPUGhMbUl1dGhIX1cybVpjWTJHbnRmdGxDNy1Ga2hZcWM0aVhxcFd2UDk5X1ZyN3k4VFdDYlhubjNHdw?oc=5", "source_name": "MarketBeat", "published_at": "2022-06-14T13:57:51+00:00", "published_display": "14 Jun 2022 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Institutional Ownership 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE95cXU0aVpZNkhtZGFHVkdwa2pJcHJlVDZPMGNCU1hOTVFtMnpRVU54OTR3cXlsNFFsLTFaTTJtVkE3UUVaX2xwLS1MM1BiOThBNVRzdkMta2Z5Wk9JZEdKbzBOemVoRFNiaXAzM1RDLUJPWklQZFg4Q19B?oc=5", "source_name": "MarketBeat", "published_at": "2022-06-13T21:28:19+00:00", "published_display": "13 Jun 2022 21:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech company Senti Bio to go public via $600 mln SPAC deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxON210ODdwaDR2QTN4LWhBSEoyQzNrT1JaN29FSlZnYkZKOUJyeHlkRWZwY0dEZjRMN25TR1ExbmQxZTB6ZzhfM0o4QmZ1V0kxS2x4RXB0N2JMNVR4REZtVTBRZWVkTXpXeURHOG5DY0MyUzBtUmVnVzlDR20tSEE3WGQ3cVBDclNhRXZVX2NhUVd0aXVadDUzbkllRkVVdVA0dTk4SkdSOA?oc=5", "source_name": "Reuters", "published_at": "2021-12-20T08:00:00+00:00", "published_display": "20 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio and Dynamics Special Purpose Corp. Announce", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wJBVV95cUxOUC1DcTJWdzdmaThnM2Y5cm8zc0ZCbmVnZWk3M0E4X01FU2tfZmgwVVMzY2c4YUxDY0cyU2dKbDhtUENKOFdYa2hXR2NiLXFWcTN2VlZ0ekE1SUhRRUpVclhWSllDbUhLZnU2cmREY0JxUkY3R2NBOW1ZVENaRlBtd0FjM1p5QWw4SkxKQTN2REJjdWpZVjFYYlV3YXBZa1UwNmQ4U0N6b25UZ1VCcHdzdmJaOU5sRF8wZVdxX3FLWDhhdXVtNkxxUXUwMTB3ZU93WFJ2cVZ4cTlJQnUxSkJjY1Azal9LSGQ2LWVreWN1TlZKcXRmTE5teVpkRDZhMEdDV2treWZwWElYaERiZWNXTU5pYXpxTHBsWWRMbHdGRXVfWng0MlZOdnhDdUlZYVZ3aTVtMWExeW5Tek9XWU9aNVhNMVp4T0Q0RkFXNWVDVFdEaEFOUUNFRTdzSTUtTU9lQU9PRHEwUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-12-20T08:00:00+00:00", "published_display": "20 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "$Senti Biosciences (SNTI.US)$", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPdEltYU5LdHNNck5vX1BJT0ZlbDlrNmppZ2R2TXZWUTd5SHRUR3BPOTNNYXRtTDZXaTl1bVN4djNqUXV0UDREejNTZW1uZkE0VGRsQWNtZjd2bDdacW9aNnFPZGwyYWJRT3FqakJDWmFtNnJLVFZ1cjJ4OTlqT3dVSE5WcFh3dw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-21T23:58:00+00:00", "published_display": "21 Jul 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) outlines CVR-only merger, reverse split and note share issuance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPMFFZdEY5SHVkdHMzU3BDWldpWXVZTmxaM0lvekh4RnktZnVRMmlkNUowbVhtVlA1cVMwb2VJS0dQLXlla1dBVGluWVhfa1o0VDB1alozMGZlLU5UZzl6VS1ocTZRTjFBMWg0NUU5bFBlZFBZMWpmRWRNN29uRzJpcHVmSVZWcVRhbDdyaE50OTlvNnhPTm8yTXY2bFcxaHlnYVNCTER4b1lVcnA2SFpUOUNfVjF5Snk1SEw3NGJfV0tlZHRUOUdhZlEyNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-21T22:01:14+00:00", "published_display": "21 Jul 2026 22:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026)", "summary": "This article reports on an ARS SEC filing by Senti Biosciences Holdings, Inc. (SNTI) on July 21, 2026. The filing has a low impact and neutral sentiment, and was accepted by the SEC EDGAR at 05:18 PM on the same date. The article also provides recent news and other SEC filings re", "url": "https://www.stocktitan.net/sec-filings/SNTI/ars-senti-biosciences-holdings-inc-sec-filing-31b77d1430f0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T22:10:25", "published_display": "21 Jul 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (NASDAQ: SNTI) Share Price, SNTI Stock News, SNTI Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE51MEdiLVZXaXZSdWJyWWZSUWQ4ZGJSa0U3LUx6RncyRGRwVHgzRk52N3VoTTEzNjdkQlNmYWJ5dHVvYUFnd1NHWngtOEZuTFZUQmZkWkd3?oc=5", "source_name": "Kalkine", "published_at": "2026-07-20T14:53:00+00:00", "published_display": "20 Jul 2026 14:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com", "summary": "This article from Investing.com reports on a Form 13D/A filing related to Senti Biosciences Holdings, specifically for activity on July 16. It notes a -4.94% change for SNTI. The content primarily focuses on financial market data and investment-related topics, including stock per", "url": "https://ng.investing.com/news/stock-market-news/form-13da-senti-biosciences-holdings-for-16-july-93CH-2603666", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T12:10:58", "published_display": "17 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Senti Biosciences Holdings Inc For: 16 July", "summary": "This article announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. on July 16, 2026. This SEC filing is typically related to registering securities for offering, indicating potential capital-raising activities for the company. The brief notice highlights the immed", "url": "https://ng.investing.com/news/stock-market-news/form-s3a-senti-biosciences-holdings-inc-for-16-july-93CH-2602398", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T00:09:35", "published_display": "17 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. The filing date is noted as July 16, and the article provides no further details beyond this announcement. The piece includes financial data, market indices, and other investment", "url": "https://za.investing.com/news/stock-market-news/form-s3a-senti-biosciences-holdings-inc-for-16-july-93CH-4371736", "source_name": "Investing.com South Africa", "published_at": "2026-07-16T18:14:03", "published_display": "16 Jul 2026 18:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) backer plans merger and $6M funding", "summary": "Celadon-affiliated entities, holding a 54.6% stake in Senti Biosciences (SNTI), have reported a merger agreement with Senti Biosciences Holdings. This merger involves the acquisition of Senti's Gene-Circuit-enabled pipeline, including SENTI-202 rights, through Parent (Celadon Par", "url": "https://www.stocktitan.net/sec-filings/SNTI/schedule-13d-a-senti-biosciences-holdings-inc-amended-major-sharehold-89c3ed4448da.html", "source_name": "Stock Titan", "published_at": "2026-07-16T18:10:51", "published_display": "16 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Stockholders Could Receive Up to $60M From SENTI-202", "summary": "Senti Biosciences Holdings (NASDAQ: SNTI) announced a strategic transaction where its Gene-Circuit-enabled pipeline, including SENTI-202, will be acquired by a new private biotechnology company controlled by its largest investor, Celadon. In return, SBH equity holders will receiv", "url": "https://www.stocktitan.net/news/SNTI/senti-biosciences-holdings-inc-announces-a-strategic-transaction-to-m90r9xa30iro.html", "source_name": "Stock Titan", "published_at": "2026-07-16T01:10:25", "published_display": "16 Jul 2026 01:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences to spin off gene therapy unit for CVR", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQdzgtVFFUNTMxYmc1VEVBRlMyaThLZjd6ZmNUZ2Nfem1fNGIyYi1qVXZqVm5QRi1OVm03M29RZmpTV1h4ZW9IejBCdm83ZFR5aW5WWlVwamVZNXpYUnNxQldfWmotQ0x2YnVuemI5LUFxTGVVMWM1QnlHVnQwLTQyYXk3U0pRc2g4bWJpcmRLdjREZFQwZV9XY2VIdzVFXzlKS0F2dmoxTXA2d00zVFlLazh3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T12:03:15+00:00", "published_display": "15 Jul 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial\u2122 Te", "summary": "Senti Biosciences Holdings, Inc. (SBH) announced a strategic transaction where a newly formed private company, NewCo, will acquire SBH's Gene-Circuit-enabled pipeline, including SENTI-202. In return, SBH equity holders will receive a contingent value right (CVR) providing up to $", "url": "https://finance.yahoo.com/healthcare/articles/senti-biosciences-holdings-inc-announces-113000590.html", "source_name": "Market source", "published_at": "2026-07-15T11:48:02", "published_display": "15 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs", "summary": "Senti Biosciences has announced a merger agreement with a Celadon Partners affiliate to divest substantially all of its existing business and pipeline. Senti will remain public, retaining certain IP and early-stage programs, while stockholders could receive up to $60 million in c", "url": "https://www.tradingview.com/news/tradingview:b4ae19032a637:0-senti-biosciences-to-divest-operating-business-to-celadon-affiliate-holders-get-up-to-60m-cvrs/", "source_name": "TradingView", "published_at": "2026-07-15T11:48:02", "published_display": "15 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform", "summary": "Senti Biosciences Holdings (SBH) announced a strategic spin-off of its Gene-Circuit pipeline, including SENTI-202, into a new private company, NewCo. SBH will now focus on its Regulator Dial platform for controllable genetic therapies, while stockholders could receive up to $60 m", "url": "https://www.quiverquant.com/news/Senti+Biosciences+Holdings+Announces+Strategic+Spin-Off+of+Gene-Circuit+Pipeline+and+Plans+Focus+on+Regulator+Dial+Platform", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T11:42:17", "published_display": "15 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article provides the \"Price to book forward\" value for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific financial metric for the company at a certain period is av", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T10:40:56", "published_display": "01 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article provides a financial metric\u2014enterprise value to EBIT forward\u2014for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a data point from TradingView's financial section, offering a snapshot of this specific valuation metric without further analytical comm", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:11:02", "published_display": "27 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI)", "summary": "This article provides an overview of Senti Biosciences Holdings, Inc. (NASDAQ: SNTI), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It highlights the company's earnings, revenue, market capitalization, and volatility, whi", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-27T05:40:34", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Senti Biosciences Holdings, Inc. \u2013 NASDAQ:SNTI", "summary": "This article displays the \"Price to sales forward\" metric for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It is a brief financial data point from TradingView, indicating that the market for SNTI was closed with no trades when this information was presented. The article is a ", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:15", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Senti Biosciences Inc (SNTI), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. SNTI's current price momentum score is 6.28, and it is trading between a resistance lev", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/technical", "source_name": "TradingKey", "published_at": "2026-06-26T03:40:34", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Senti Biosciences Holdings, Inc. (SNTI) stock, including price targets from three analysts, with a maximum estimate of $15.00 and a minimum of $12.00. It also covers SNTI's current price, historical performance, volatility, market capitalizati", "url": "https://www.tradingview.com/symbols/NASDAQ-SNTI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:15", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes", "summary": "Senti Biosciences (SNTI) has registered 15.97 million shares of common stock for resale, tied to Senior Secured Convertible Notes issued in May 2026. This move, while not generating direct proceeds for the company, represents a significant potential dilution, as the shares could ", "url": "https://www.stocktitan.net/sec-filings/SNTI/s-3-senti-biosciences-holdings-inc-shelf-registration-statement-36aa7bdfbe09.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:11:17", "published_display": "18 Jun 2026 21:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Senti Biosciences Inc (SNTI) has an earnings forecast score of 8.50, placing it 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00 for SNTI, with a \"Buy\" rating based on the opinions of 4 analysts. The company's EPS for the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:11:17", "published_display": "18 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Senti Biosciences Inc (SNTI), noting its current valuation score of 6.82, ranking 295 out of 388 in its industry. It highlights the company's current P/E ratio of -0.65, which is significantly below its recent high and above its recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:38", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Senti Biosciences Inc (SNTI), noting that relevant financial data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price and marke", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:08:58", "published_display": "17 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Inc (SNTI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Senti Biosciences Inc (SNTI). It notes that no dividends have been distributed in the past five years and details several upcoming merger-related stock splits scheduled for July 16, 2024, at a 10-to-1 ratio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-snti/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:08:57", "published_display": "17 Jun 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI - Senti Biosciences Holdings Inc Options", "summary": "This article provides a comprehensive financial overview of Senti Biosciences Holdings Inc (SNTI), detailing its current stock performance, key financial metrics, and company statistics. It includes data on market capitalization, income, sales, analyst recommendations, and variou", "url": "https://finviz.com/stock?t=SNTI&ty=oc", "source_name": "Finviz", "published_at": "2026-06-09T20:51:00", "published_display": "09 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SNTI - Senti Biosciences Holdings Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news feed for Senti Biosciences Holdings Inc (SNTI). It includes key financial metrics, stock performance data, analyst ratings, and a chronological list of recent company news releases, focusing on clinical trial advancements ", "url": "https://finviz.com/stock?t=SNTI", "source_name": "Finviz", "published_at": "2026-06-07T08:12:01", "published_display": "07 Jun 2026 08:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase", "summary": "Senti Biosciences Holdings announced its Q1 2026 financial results, highlighting significant progress in its SENTI-202 program for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), which is now advancing into a pivotal phase after positive FDA feedback supporting a single-arm", "url": "https://finance.yahoo.com/sectors/healthcare/articles/senti-biosciences-holdings-reports-first-124500488.html", "source_name": "Market source", "published_at": "2026-05-29T17:12:04", "published_display": "29 May 2026 17:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR", "summary": "Senti Biosciences, through its subsidiary Senti Holdings, has sold $10.0 million in senior secured convertible notes to Celadon Partners SPV 24, as per a previously announced agreement. The company also detailed potential future \"Subject Transactions,\" which could include additio", "url": "https://www.stocktitan.net/sec-filings/SNTI/8-k-senti-biosciences-holdings-inc-reports-material-event-eea24fde770f.html", "source_name": "Stock Titan", "published_at": "2026-05-26T20:10:09", "published_display": "26 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Advances SENTI-202 to Pivotal Trial With Donor X Selection Strategy", "summary": "Senti Bio is advancing its allogeneic CAR-NK program, SENTI-202, to a pivotal trial based on a \"Donor X attribute\" strategy that significantly improved response rates in heavily pretreated AML patients. This attribute, found in about 50% of adult donors and independently detectab", "url": "https://www.clinicaltrialvanguard.com/news/senti-bio-advances-senti-202-to-pivotal-trial-with-donor-x-selection-strategy/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-05-18T22:48:02", "published_display": "18 May 2026 22:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note Structure", "summary": "Senti Biosciences, Inc. (SNTI) is facing significant refinancing and liquidity risks due to a costly note structure requiring a 200% cash payment at maturity or default. The company's inability to generate sufficient cash flow could lead to asset sales, dilutive equity raises, or", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1981674/senti-biosciences-faces-severe-refinancing-and-liquidity-risks-from-costly-note-structure/", "source_name": "The Globe and Mail", "published_at": "2026-05-17T06:10:27", "published_display": "17 May 2026 06:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Secures FDA Support for SENTI-202 Donor Selection Strategy in AML", "summary": "Senti Biosciences gained FDA support for its SENTI-202 donor selection strategy in relapsed/refractory AML, based on post-hoc analysis showing a significant difference in remission rates depending on the NK cell donor. The company will now exclusively use \"Donor X\" derived cells ", "url": "https://www.clinicaltrialvanguard.com/news/senti-biosciences-secures-fda-support-for-senti-202-donor-selection-strategy-in-aml/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-05-15T22:12:03", "published_display": "15 May 2026 22:12", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio (NASDAQ: SNTI) wins FDA RMAT backing and lines up $40M funding", "summary": "Senti Biosciences (NASDAQ: SNTI) has reported a narrowed net loss and significant progress for its lead program, SENTI-202, including positive FDA Regenerative Medicine Advanced Therapy (RMAT) backing for a pivotal trial in relapsed/refractory AML. The company also secured a stra", "url": "https://www.stocktitan.net/sec-filings/SNTI/8-k-senti-biosciences-inc-reports-material-event-b6edcb946aa3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:10:28", "published_display": "15 May 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/senti-biosciences-holdings-announces-positive-124000159.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:40:00+00:00", "published_display": "14 May 2026 12:40", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Secures Up to $40 Million Financing and FDA Endorsement for SENTI-202 in Relapsed/Refractory Acute Myeloid Leukemia", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOMHJXMTgtWk45MDN6aE5xU0pkN25LeGdDemFYbVEyRlVKcEh6Z0JLUHk2M2VQNk1mUnpqbk5oaUhaRTc3cU9lRnVUR3UwM25ZMTh4U0dsUDdwd0dCVV9MSmZ0WDFPbDhyay1IMGcyc1hhMG5scXQtU0lOQkxtREhNbDdkUTlYNHdISGdKRWZ0Y2ttZnlCblRldU92ZEQ4MUgyVXNLV3NHLURJWnZYZWpBUEItelJ4RlVFMWo1X0FndkkwV1NVWHdnZElzRk4wT0FWNG9ZNFBVeDVqUzlCeGp5VXZudmltdFZudkV0WExodGh1ZmxldVFLTzZ2RWU?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences, Inc. SEC Filing (Apr 30, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNQl9YX0lGRk5ZWFhUVVlNNUVTOTlFMFRHNmhvbEJBOFpGTEhfQVROZXplYUhib3FDSkZfUFo0aTRQeGkxTXhtSXBwQ1BtZ25qQWFfRm1Qa2RmMVNjRTdwVWZOMWt5elhpTms5TmxBcnJRTGpBeDJIQ0N1ZFpJVFFjcEdMczdFMjhUSkhfR2dUM29QTzF2MFdiMFZkVHhjSktEV2t3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences completes holding company reorganization, stock continues on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOOEVmNzg2X2VLOXJZQTRwaUlSSUlpNXhLOHZhMjNaRndqTVZhZm9NLWxYa1d4V0FCbVBMV2NhcXFZcXJSSUZDT043a1ROaW1vSUU4Z1gweFUyLXdWZm93NE5mMUNsaVV4cFBmSHNsNEVoRzI4SlM4c25XNW1rcXZxZ2NvVXVPd09tNG5PT3hvTDdiUzI4NUJoMF9yb0lnN2ZXOHRXdVZ6N1g1M2JhaG5fcHhvZktCWVlOS0VTUDE0a1hLLWdXeHFzSzZTOG5fdkNtSFI0bUtwWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bios to implement tax-free holding company reorganization, shares to convert and continue trading as SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxQRkExeHlGbU96cUJRYzNaNHZfa1lBWVRKcDg5dlRkWDBCVTZNaDBRSWIwcGtiTkhhNjZ6X0ZWVmFJc3F4YU85RFlhcHJaMlVUekxEdk9QNVZZTWcwOFd3V0lYZ0Vad2FBVDcwYkRrd2owMjZVZ0g4S2hxdmJxYXVBY1FMem12NTg0WTFnN29XbENKTXdNc0hJZ09WWloyLWNJVGpDMjg0MkZWeHRpclhPYzBNUV84Sk5VbUpxVnMyOElmWXY2NXdlN1haQnpfWUlfb20xYmd5V1RPVy1ReTloWVMxbnZSdE9aWjVjaWR5RVl4cDZuektMLWFvSnBtTWo5eHc?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences stock rating held at Buy by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOWxXc1d3cUZ1YmFPblZsWFFlOGJ6MXJNdllYTmQySzRfd0JNLTRFU2hvQWtxX2o1VDdzOUdsOVZVc0ZzcE5ZMDAxMDhUWmhfWU5DbElueU5FOTRRUTIwUWhjU1psam5TMF85MkFUVTd6UjRkVy1GandWWWp6eVRmbllIQlg0Q2kxSWpBY01ZWS1HNktoSXk4Q2tvMGhTWEg3YkNCZ19TcHp0UG5mUFFmMmJBaGR3OHFNVkhj?oc=5", "source_name": "Investing.com", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants special status to Senti Bio's leukemia therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWWpScS1GSENMRXZwaVp5SlZEN3RnWEkta1d1NDhMbVhuWnF3OWhBVkxMQkhlMUd4aHJPdnBuWHEtbTNrQ2lHai1aNzg3bi1FZmU1LWx4TzFxeHVNQ2hnSF9TTE5SX3ZKQlNwcHRvbEF5dVV3el9tVTB5eEs2V2R1eVdiM29pMkVrY0RKem1penRtNHBnbzl3ODROMExXeV9LalAwc0FZZEE0by1HYk5XS1BHS01ZM1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOQnhtTXBDbExDcjJ0MHRzY3FPclRLRnIzX3Q5WWRpcEtIdDh4T3p1MWYwSVZEbkxqZkh1NzFMU0hINk9TcU5fazE1TXFNNEhCRWgyU1JJVndwdXlsU2Z4enNMQjZjOXo0RXlOZDM3eXZoTzFxMFhKdGhlT25JYkJKNnNGVXEyZzRKdmM3UWxqRDB6MEJMaW9vZUhNd2xvT0NzX0Fn?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences: Understanding the Market Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9CRmVveW5fX09OeV9nZHlkN2ZfVkFEZXVTOFJkRGZ6eTVmQXZJZW5OeXlrSVR4ZC1rYkRIT21rY3NqUVkwb2VFeURncktsUFp4d25xMW81V2VOVndfdEZsSUczU0hNczg0ZnhSUHhLTUs5dXd5dXFZVEpOQXB2bkU?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5kN3ZBN3pvX1pBSUc2eWdveFF4NG1jZGNxcTdrNWZyd3FqVm1QS2RlcW5iRkZ1OF9BTGtKTzFBX0I2TngybzJwbHU4a3ZKUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-09T15:18:43+00:00", "published_display": "09 Dec 2025 15:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQTi04N0R6dU9IODJMaDlrbFRESjhpcWhzYUtBaFMyY3BXb2Zvam53cENrMkRTXzR6dWtSRUQ4TVJsTkt1WHlxZ0Rzd01RbHBCMGdiVDduVWtmMk91MjZvaVdVMjRpZ19lRGh6RFJ5VTc3RVBWbnNLcEFNa3ozMy1BenVhMXc5OVRJY25wMUlWaUpPVmVFdHpUQkE3WFpWSnc?oc=5", "source_name": "OncLive", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Holdings (SNTI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBrRW41VEN4d2FucFBYOExFelJ1UV9fVkRtSThCV2l2ZExubXpySUx5dTJrdDFwb0RzZkJzRG1hRDM5TjNSMU5oU3dCUUdZVmpIa0lZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:57:19+00:00", "published_display": "24 Apr 2025 16:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Stock Forecast and Price Target 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5EXzNkM2t3bTZjOFBoZzVBZ3llbGJBdkRJWUpEN1VzeDB1aWhSTDBMalpiNTVhNXE1ODl2bmwwR2VaVHh2Qlpoa09uZFhKRWYzbW4xbFR0bmhWTUtUQlNNM25XQmJXUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:41:28+00:00", "published_display": "11 May 2024 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1lOV9sSlZKNTF6VlZIcmk3M1gwTmM1LWhDTXlSRFlZTkJrTWpsY09KeVNwM25YNDlnNjh1Q3VDdzdZbWV6UzJ1b3pSaWxGN3g5ZjhBeFVJYw?oc=5", "source_name": "Moomoo", "published_at": "2023-07-31T05:06:35+00:00", "published_display": "31 Jul 2023 05:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Earnings Date and Reports 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE8tdlNwQ3VYaEJVODlMVkI2bnpKMUgwVWs0Mm1IU0FFVVJja1hPUGhMbUl1dGhIX1cybVpjWTJHbnRmdGxDNy1Ga2hZcWM0aVhxcFd2UDk5X1ZyN3k4VFdDYlhubjNHdw?oc=5", "source_name": "MarketBeat", "published_at": "2022-06-14T13:57:51+00:00", "published_display": "14 Jun 2022 13:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Biosciences (SNTI) Institutional Ownership 2026 $SNTI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE95cXU0aVpZNkhtZGFHVkdwa2pJcHJlVDZPMGNCU1hOTVFtMnpRVU54OTR3cXlsNFFsLTFaTTJtVkE3UUVaX2xwLS1MM1BiOThBNVRzdkMta2Z5Wk9JZEdKbzBOemVoRFNiaXAzM1RDLUJPWklQZFg4Q19B?oc=5", "source_name": "MarketBeat", "published_at": "2022-06-13T21:28:19+00:00", "published_display": "13 Jun 2022 21:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech company Senti Bio to go public via $600 mln SPAC deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxON210ODdwaDR2QTN4LWhBSEoyQzNrT1JaN29FSlZnYkZKOUJyeHlkRWZwY0dEZjRMN25TR1ExbmQxZTB6ZzhfM0o4QmZ1V0kxS2x4RXB0N2JMNVR4REZtVTBRZWVkTXpXeURHOG5DY0MyUzBtUmVnVzlDR20tSEE3WGQ3cVBDclNhRXZVX2NhUVd0aXVadDUzbkllRkVVdVA0dTk4SkdSOA?oc=5", "source_name": "Reuters", "published_at": "2021-12-20T08:00:00+00:00", "published_display": "20 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senti Bio and Dynamics Special Purpose Corp. Announce", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-12-20T08:00:00+00:00", "published_display": "20 Dec 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 59, "sentiment_summary": {"positive": 13, "negative": 5, "neutral": 41, "score": 52, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 3.1, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 0.44, "latest_week": "2026-07-17", "one_week_move": -57.6, "four_week_move": -53.1, "twelve_week_move": -59.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.789637, "market_dynamics_buy_signal": false, "relative_strength": -69.532809, "fair_value_gap": -85.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.7805, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-57.6% over one week, -53.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "MarketBeat", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Macro sensitivity", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-57.6% over one week, -53.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "$Senti Biosciences (SNTI.US)$"}], "updated_at": "2026-07-23T05:31:05.516117+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}